Skip Navigation


JAC Advance Access originally published online on October 21, 2004
Journal of Antimicrobial Chemotherapy 2004 54(6):1158; doi:10.1093/jac/dkh451
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/6/1158    most recent
dkh451v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Frippiat, F.
Right arrow Articles by Derue, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frippiat, F.
Right arrow Articles by Derue, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC vol.54 no.6 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved

Correspondence

Place of newer quinolones and rifampicin in the treatment of Gram-positive bone and joint infections

Frédéric Frippiat1,2,*, Françoise Meunier3 and Geneviève Derue1

Departments of 1 Internal Medicine and 3 Microbiology, Centre Hospitalier Jolimont-Lobbes, rue Ferrer 159, B-7100 Haine-Saint-Paul; 2 Department of Internal Medicine, Centre Hospitalier Universitaire du Sart Tilman, Bâtiment B 35 Sart-Tilman, B-4000 Liège, Belgium

Keywords: moxifloxacin , rifampicin , bone infections , joint infections

The first 10% of the full text of this article appears below.

Sir,

We have read with interest the article by Darley & MacGowan1 and would like to comment on some aspects.

Firstly, it is stated that newer quinolones, e.g. moxifloxacin and levofloxacin, should not be considered in antibiotic treatment of Gram-positive bone and joint infections because data on penetration, efficacy and use against Gram-positive pathogens other . . . [Full Text of this Article]

* Corresponding author. Tel: +32-4-3667241; Fax: +32-4-3668583; Email: f.frippiat@chu.ulg.ac.be


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
O. Grossi, J. Caillon, C. Arvieux, C. Jacqueline, D. Bugnon, G. Potel, and A. Hamel
In Vivo Efficacy of Moxifloxacin Compared with Cloxacillin and Vancomycin in a Staphylococcus aureus Rabbit Arthritis Experimental Model
Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3401 - 3403.
[Abstract] [Full Text] [PDF]